Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
PaperCitations, authors & open-access status
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 27 citations, 2021 year and gold oa status.
27
Citations
2021
Year
gold
OA Status